Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

a direct license with Orcrist. BioMS assigned all BioMS owned patents relating to HYC750 and transfered all HYC750 assets to Orcrist. Under the terms of the agreement, BioMS will receive certain milestone payments in addition to a royalty on net sales of products which otherwise would have infringed on patents related to the HYC750 technology.

BioMS also ceased all development activities with respect to BioCyDex. Future development or licensing activities will be the responsibility of BioCyDex.

Financial Results

The consolidated net loss for the year ended December 31, 2008 was $0.5 million or ($0.01) per share compared with a consolidated net loss of $47.2 million or ($0.56) per share for the previous year. The consolidated net income for the three months ended December 31, 2008 was $0.3 million or $0.01 per share compared with a net loss of ($11.7) million or ($0.13) per share for the previous year.

Revenue of $52.6 million was recorded for the year ended December 31, 2008 compared to $Nil for the year ended December 31, 2007. The revenue is the result of the amortization of the upfront payment and development milestone received from the Agreement with Lilly. Investment income earned on funds invested for the year ended December 31, 2008 increased to $2.4 million from $1.6 million for 2007 due to the increase in cash and cash equivalents as a result of the Agreement with Lilly. The increase was partially offset by a general reduction in interest rates experienced in the market. The investment income is earned from the short-term investment of cash reserves in low risk term deposits and bankers acceptance notes.

Total consolidated expenses for the year ended December 31, 2008 were $61.9 million compared with $48.0 million for 2007. Total consolidated expenses for the three months ended December 31, 2008 totaled $16.5 million as compared to $12.1 million in the same quarter the previous year.

Research
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... and NEW YORK ... (NASDAQ: PTBI ), a biopharmaceutical company advancing ... announced today that its Korean marketing partner, Hanmi ... marketing approval in Korea from the country,s Ministry ... Korea Testing & Research Institute (KTR) for MuGard, ...
(Date:3/31/2015)... 31, 2015 Diasome Pharmaceuticals, Inc. ( ... Inc., that a United States patent has recently been ... , Entitled “Lipid Construct for Delivery of ... matter claims related to the use of Diasome’s proprietary ... injected insulin to more effectively reach the liver’s metabolic ...
(Date:3/30/2015)... Calif. , March 30, 2015  Multiple new ... positively affect several important health factors. From their impact ... to their positive effect on both gut health and ... 2015 (EB) detail our latest understanding of walnuts, inner ... Boston , this annual meeting attracts an ...
(Date:3/30/2015)... 2015 US-Australian drug discovery company, Novogen Ltd, ... Inc., and Yale University, on March 27 released pre-clinical ... presented as an oral presentation by Professor Gil ... the 62 nd Annual Scientific Meeting of the ... CA. In both in vitro ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
... Lynn Jordan , ... Introduction , ... commonly carried out using manual pipetting. As the demand for greater ... a necessity for most laboratories. The most critical aspect of an ...
... Jeff Cunningham and Lynn Jordan , ... USA , Introduction , ... an optional accessory to the Sciclone Advanced Liquid Handler (ALH). This device ... or columns of 96 and 384 well microplates for purposes of liquid ...
... Geoffrey Grove, Ed Alderman Applied Science and Technology, Caliper Life ... Monica Adams, Jason Brennan Development Integration, Amersham BioSciences, 800 ... Overview , ... to eliminate the requirement for extended bacterial growth prior to sequencing. ...
Cached Biology Technology:384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler 2384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler 3384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 2Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 3Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 2Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 3Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 4Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 6
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
(Date:3/11/2015)... March 11, 2015   The Sync Project™ ... to scientifically measure and harness music to improve ... biometrics and objective measurements of physiology, enabling the ... scale in large populations. It is designed for ... clinicians perform rigorous studies and accelerate the discovery ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... The technology - which makes plants significantly more ... use by US agricultural company Becker Underwood in collaboration ... spraying crops with jasmonic acid - a chemical naturally ... reduces pest attack. But crops treated with the chemical ...
... A chemotherapy drug that is supposed to help save ... fatal allergic reactions. A new study from ... pharmacovigilance program at Northwestern University Feinberg School of Medicine ... the FDA,s Adverse Event Report System between 1997 and ...
... Humans, from ancient exchanges of food to modern day home mortgages, ... on their own. It,s the basis of the economy, and it ... receive a payoff in return for taking a risk. When ... of the housing market, the economy slows. The willingness to ...
Cached Biology News:Natural seed treatment could drastically cut pesticide use 2Common chemotherapy drug triggers fatal allergic reactions 2Common chemotherapy drug triggers fatal allergic reactions 3Researchers shed light on trading behavior in animals -- and humans 2
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
Rabbit polyclonal to EDG2 ( Abpromise for all tested applications). entrezGeneID: 1902 SwissProtID: Q92633...
... Synthetic peptide derived from the internal region ... Specific for the internal region of ... identifies the target band at ~590 kDa. ... secreted media from primary tracheobranchial epithelial cultures ...
...
Biology Products: